Category: Impacting News

ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer

Innovent Biologics Announcement at ASCO Innovent Biologics , Inc. ( HKEX: 01801 )(OTC: IVBXF )  announced that the clinical data of a randomized controlled Phase 1b study evaluating IBI310 (anti-CTLA-4 monoclo-nal antibody) in combination with sintilimab as neoadjuvant treatment of...

Read More

June 13, 2024

0

Broadcom Inc. Announces 2Q Fiscal Year 2024 Financial Results, Quarterly Dividend and Stock Split 10-1

Broadcom Inc Announcements What analysts heard from the Artificial Intelligence ( AI ) firm Broadcom Inc is promising and exciting news about the past and excellent expectations regarding the future. The Story The Artificial Intelligence Broadcom Inc. ( AVGO )...

Read More

June 14, 2024

0

Good News for Vertex Pharmaceuticals and for Crispr Therapeutics

Vertex Announces CASGEVY™ Reimbursement Agreement with NHS England Vertex Pharmaceuticals ( VRTX ) announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta-thalassemia ( TDT ) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel).  The United Kingdom...

Read More

August 27, 2024

0

Regenxbio Announces Positive Results of its Product RGX-121 for Hunter Syndrome  

Regenxbio Positive Results Regenxbio ( RGNX ) announced positive results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for patients with Mucopolysaccharidosis Type 2 ( MPS II ), also known as Hunter syndrome. The results were presented at the Society...

Read More

September 5, 2024

0

Incyte Announces the FDA Approved its Opzelura Cream for the Treatment of Vitiligo

Incyte Announces FDA Approval of Opzelura Cream for Vitiligo Incyte ( INCY ) announced today, July 19, 2022, that the United States Food and Drug Administration ( FDA ) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of...

Read More

July 20, 2022

0

FDA Approval of argenx Product VYVGART Hytrulo for Patients with CIDP

argenx in the NEWS argenx SE ( ARGX ) announced that the U.S. FDA has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy ( CIDP ). VYVGART Hytrulo is approved for CIDP as...

Read More

June 24, 2024

0

Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

Seagen, Astellas Pharma & Merck Collaboration Seagen ( SGEN ) and Astellas Pharma ( ALPMY ) have entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen’s and Astellas’ product PADCEV® (enfortumab vedotin-ejfv) with Merck’s ( MRK...

Read More

July 26, 2022

0

Nurix Therapeutics: Positive Results from Ongoing Clinical Trial of NX-5948

Nurix Therapeutics in the NEWS On June 16, 2024, Nurix Therapeutics ( NRIX ) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase ( BTK ), being evaluated in an ongoing Phase...

Read More

June 25, 2024

0

Travere Therapeutics Announces Full FDA Approval of FILSPARI®

Travere Therapeutics Approval Travere Therapeutics, Inc., ( TVTX ) announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. In February 2023, based...

Read More

September 11, 2024

0

Verona Pharma Announces the US FDA Approval of Ohtuvayre™ for the Maintenance Treatment of COPD

Verona Pharma in the NEWS Yesterday, June 26, 2024, Verona Pharma plc ( VRNA ) announced that the US FDA has approved Ohtuvayre (ensifentrine) for maintenance treatment of chronic obstructive pulmonary disease ( COPD ) in adult patients. Ohtuvayre is...

Read More

June 27, 2024

0

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0